Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy

Eligibility criteria:

• Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of the prostate within 12 months of registration;
• Any one of the following clinical stages:
• T3 disease, any N stage, M0 with any Gleason score and any prostate-specific antigen (PSA); negative 2.5;
• Zubrod Performance Status 0-1 within 16 weeks prior to registration; (8/16/07)
• Age ≥ 18;
• Serum creatinine within 4 weeks prior to registration (8/16/07)
• Corrected serum calcium ≥ 8.4 and ≤ 10.6 mg/dl within 8 weeks prior to registration; note: for patients with an albumin of 4.0, corrected calcium=measured calcium. The formula for corrected calcium if serum albumin value is above or below 4.0 is as follows: Corrected calcium (mg/dl) = (4 - [patient's albumin (g/dl)] x 0.8) + patient's measured calcium (mg/dl)
• Patients who are sexually active must be willing/able to use medically acceptable forms of contraception, as the treatment involved in this study may be significantly teratogenic.
• Patient agrees to refrain from using all products listed in Section 9.2, "Non-permitted Supportive Therapy";
• Post-prostatectomy patients are eligible.
• Patient must sign study specific informed consent prior to study entry.

Ineligibility criteria:

• Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; e.g., carcinoma in situ of the breast or oral cavity are permissible;
• Patients with baseline T scores of ≤ -2.5 are excluded.
• Patients with baseline calculated creatinine clearance < 30 mL/min (estimated by Cockcroft-Gault formula below) are excluded. creatinine clearance male = [(140 - age) x (wt in kg)] / [(serum creatinine) x (72)]
• Prior bisphosphonate therapy;
• Prior pelvic radiation (other than for current prostate cancer) or prior systemic radiotherapeutic agents, such as strontium or samarium;
• Patients receiving systemic chemotherapy, steroids, growth hormones, or calcitonin;
• Patients with a history of Paget's disease or with uncontrolled thyroid or parathyroid dysfunction or with other diseases that influence bone metabolism;
• Known hypersensitivity to zoledronic acid or other bisphosphonates;
• Active dental problems at study entry, including infection of the teeth or jawbone; dental or fixture trauma; or a current or prior diagnosis of osteonecrosis of the jaw, exposed bone in the mouth, or slow healing after dental procedures;
• Recent or planned